You are now leaving helsinn.com

Please click 'Continue to external site' if you want to continue.

Pipeline

We’re working to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes therapies aimed at providing new solutions in cancer care and rare diseases where no options currently exist, with a goal to help lift the burden of cancer for patients.

Robust R&D Pipeline with significant potential

Near-term and long-term pipeline, securing launches over the coming years.

Cancer Therapeutics

Infigratinib1

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
2nd Line Cholangiocarcinoma2
1st Line Cholangiocarcinoma
Adjuvant Urothelial Cancer

HM06

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Solid Tumors with RET Abnormalities

GPX4 inhibitor

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Multiple tumors

Chlormethine

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
China – MF-CTCL3

Cancer Supportive Care

Fosnetupitant IV

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Japan - CINV4

Fosnetupitant - Palonosetron

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Pediatric CINV4

Fosnetupitant - Palonosetron IV

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
China - CINV4

Anamorelin5

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Cancer Anorexia-Cachexia in NSCLC6 patients
China – Cancer Anorexia-Cachexia in NSCLC6 patients

Other

HM04

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Ghrelin Receptor Antagonist - Prader-Willi Syndrome

HM01

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Ghrelin Receptor Agonist

Notes

The safety and efficacy of the product candidates in the above table have not been established. There is no guarantee that they will receive health authority approval or become commercially available in any country for the uses being investigated.

  1. Infigratinib is co-developed globally by Helsinn Healthcare S.A. and QED Therapeutics, Inc., a BridgeBio company, in all fields of use except for skeletal dysplasias and except in the following territories: China, Hong Kong and Macau
  2. Approved in U.S., Canada and Australia – Regulatory process ongoing in other territories
  3. Mycosis fungoides-type cutaneous T-cell lymphoma
  4. Chemotherapy-Induced Nausea and Vomiting  –  In Japan Arokaris®  only includes Fosnetupitant
  5. Approved in Japan
  6. Non-Small Cell Lung Cancer